Navigation Links
WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents
Date:5/5/2008

r uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Co
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
2. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
3. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
4. Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference
5. Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel
6. Panelists Announced for 2007 Manufacturers Forum
7. Vicus Therapeutics Chief Executive Officer to Participate in BIOTECH 2007 Expert Panels
8. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
9. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
10. Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference
11. Sensitech to Sponsor Panel Session at IQPC Cool Chain Europe 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2, 2015 VG Life Sciences, Inc., ... autoimmune and infectious diseases, announced that the U.S. ... important new composition of matter patent covering methods ... of CLIP. U.S. Patent No. ... Life Sciences, VG1177, a synthetic peptide which has ...
(Date:2/28/2015)... Increasing its efforts to resolve the GMO ... episodes of The GMO TRUTH podcast on both ITunes and ... continues its mission to discover the truth and change the ... “uncover the truth about the GMOs in our food supply,” ... Podcast is an expansion of the documentary/investigative film-making methodology in ...
(Date:2/27/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) ... of Trypsin" report to their offering. , ... providing comprehensive data on Trypsin globally and regionally ( ... North America , Latin America ... Trypsin This report focuses on three primary areas; ...
(Date:2/27/2015)... 27, 2015 FamilyFarms Group is pleased ... of State Line Farms, received the 2015 Tomorrow’s Top ... under the age of 35, who has demonstrated excellence ... honor to win the Tomorrow's Top Producer Horizon Award. ... the Top Producer Award and learning from their experiences. ...
Breaking Biology Technology:VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3The Walk a Mile Project Launches “GMO Truth” Podcast 2Global Market Report of Trypsin 2014-2018 2Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2
... Nov. 10 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: SSRX ... company focused on researching, developing, manufacturing and,marketing biopharmaceutical ... third quarter ended September 30, 2008., ... net revenues increased 21.6% over the third quarter ...
... 4:30 p.m. Eastern Time -, SAN FRANCISCO, Nov. ... on its corporate progress and financial,results for the quarter ... another quarter of significant,achievement and progress and was capped ... Dimebon. This collaboration not only gives us,access to a ...
... Restructuring and Two Divestitures of Non-Core Product Lines ... Life,Sciences, Inc. (Nasdaq: CALP ) today reported ... of two product line divestitures: the,sale of its ... and the sale of its Pharmaceutical Development and ...
Cached Biology Technology:3SBio Inc. Announces Third Quarter 2008 Results 23SBio Inc. Announces Third Quarter 2008 Results 33SBio Inc. Announces Third Quarter 2008 Results 43SBio Inc. Announces Third Quarter 2008 Results 53SBio Inc. Announces Third Quarter 2008 Results 63SBio Inc. Announces Third Quarter 2008 Results 73SBio Inc. Announces Third Quarter 2008 Results 83SBio Inc. Announces Third Quarter 2008 Results 93SBio Inc. Announces Third Quarter 2008 Results 103SBio Inc. Announces Third Quarter 2008 Results 113SBio Inc. Announces Third Quarter 2008 Results 123SBio Inc. Announces Third Quarter 2008 Results 133SBio Inc. Announces Third Quarter 2008 Results 143SBio Inc. Announces Third Quarter 2008 Results 15Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 2Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 3Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 4Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 5Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 6Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 7Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 8Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 2Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 3Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 4Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 5Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 6Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 7Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 8Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 9Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 10Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 11
(Date:2/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62114357 for DISTRIBUTED VOICE DIRECTED PAYMENT METHOD ... a new groundbreaking payment method. Payment accounts may be ... only be accessed if both the speech (the word ...
(Date:2/12/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announced ... DISTRIBUTED METHOD AND SYSTEM TO IMPROVE COLLABORATIVE ... establishes NXT-ID,s position in the emerging "Internet of Things" ... for multiple devices to collaborate with one another to ...
(Date:2/5/2015)... 5, 2015  Marken is starting its 35 th ... launched a new marketing campaign to solidify its place ... new campaign focuses on First as a ... The first headline in the series, ... with its client,s priorities. Marken recognizes the need to ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2
... The USDA Forest Service Southern Research Station (SRS) ... have officially named the fungus responsible for killing redbay ... Florida, Georgia, and South Carolina. Lead ... co-author and SRS Plant Pathologist Stephen Fraedrich, and Azerbaijan ...
... survive tough times, cells sometimes resort to a form ... reveal, autophagy can have a down side, destroying the ... a vesicle swallows a portion of cytoplasm and ferries ... often beneficial, allowing hungry cells to recycle molecules, for ...
... researchers has combined data from three independent studies ... the inflammatory bowel disorder, bringing the total number ... these are involved with the immune system,s inital ... in a process called autophagy may lead to ...
Cached Biology News:Tree-killing fungus officially named by scientists 2International team identifies 21 new genetic risk factors for Crohn's disease 2
See product name for description....
... Custom Production Service - Conjugation ... Conjugation Biotin Conjugation Fluorescein Isothiocyanate ... Conjugation Allophycocyanin Conjugation Alexa Fluor ... Alexa Fluor 405 Conjugation Rpe-Alexa ...
... Design , Customer Peptide Synthesis , 20 Amino Acid ... , 20 mg will return to customer for future usage ... 2 , Maintenance 102 days/each , ... x5 /each , Test bleed (app. 5 ...
Request Info...
Biology Products: